(CMMB) Chemomab Therapeutics Ltd. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CMMB) Chemomab Therapeutics Ltd. Complete Analysis Pack
Chemomab Therapeutics’ Business Model, Unpacked
Unlock the full strategic blueprint behind Chemomab Therapeutics Ltd.’s business model. This concise Business Model Canvas highlights how the company creates value, builds partnerships, and positions itself in the biotech market. Ideal for investors, analysts, and strategists who want actionable insight—get the full version for deeper analysis.
Partnerships
Clinical trial sites and investigators
Chemomab Therapeutics Ltd. depends on specialized hospitals and investigators to recruit rare PSC and SSc patients, capture trial endpoints, and manage safety follow-up for CM-101. In these low-prevalence diseases, clinical sites are the core channel for turning small patient pools into credible efficacy data.
CRO and trial-service vendors
Chemomab Therapeutics Ltd. relies on CROs and trial-service vendors to run multi-center trials, including monitoring, data management, site coordination, reporting, and compliance. For a clinical-stage biotech, this outside support is key to scale fast and keep studies on track across sites and regulators.
GMP manufacturing partners
CM-101 is Chemomab Therapeutics Ltd.'s lead monoclonal antibody, and it needs GMP partners for 3 critical steps: drug substance, fill-finish, and quality control. With 1 clinical asset to supply, these partners are key to keeping batches compliant and avoiding gaps in clinical supply continuity.
Regulatory and scientific advisors
Chemomab Therapeutics Ltd. relies on regulatory and scientific advisors to shape PSC and systemic sclerosis programs through FDA and other health authority dialogue. Their input helps set trial design, endpoints, and filing strategy so the asset package matches orphan-disease expectations.
- Guides FDA and agency interactions
- Shapes trial endpoints and design
- Supports orphan-disease submissions
Capital market and financing partners
Chemomab Therapeutics Ltd. relies on capital market and financing partners because, as a public clinical-stage biotech, it must fund R&D and trials before any product sales. Equity investors and financing backers help cover clinical execution and keep the pipeline moving until commercialization.
- Funds R&D and trials
- Supports pre-revenue operations
- Depends on equity backing
Chemomab’s Survival Depends on Key External Partners
Chemomab Therapeutics Ltd.’s key partners are 1) PSC and SSc trial sites, 2) CROs, 3) GMP manufacturers, and 4) regulators/advisers. These links matter because CM-101 is the only clinical asset, so every study, batch, and filing depends on outside execution.
| Partner | Role |
|---|---|
| Clinical sites | Rare-patient enrollment |
| CROs | Trial ops and data |
| GMP vendors | Drug supply |
| Advisers | FDA strategy |
What is included in the product
Detailed Word Document
A concise Business Model Canvas outlining Chemomab Therapeutics Ltd.’s biotech strategy, partners, funding, and value creation for investors and analysts.
Customizable Excel Spreadsheet
Quickly maps Chemomab Therapeutics Ltd.’s business model in a concise view for fast review and strategic discussion.
Reference Sources
Chemomab Therapeutics Ltd. Reference Sources provide a credible, traceable basis for faster due diligence and better decision-making.
Activities
CM-101 development
Chemomab Therapeutics Ltd.’s core activity is advancing CM-101, a humanized monoclonal antibody that neutralizes soluble CCL24, with work spanning discovery, translational studies, and clinical testing in inflammatory and fibrotic diseases. As of 2025, the company’s lead program has generated clinical data in primary sclerosing cholangitis and systemic sclerosis, including phase 2 development.
PSC and SSc clinical trials
Chemomab Therapeutics Ltd. runs 2 lead clinical programs in primary sclerosing cholangitis and systemic sclerosis, both built around nebokitug. Trial execution is the main value driver because it produces efficacy, safety, and biomarker readouts from 3 data streams that shape go or no-go decisions.
Translational and biomarker research
Chemomab Therapeutics uses translational and biomarker research to map CCL24 biology and track treatment response, helping select patients and test proof of mechanism in rare diseases. This work supports its Phase 2 development path and helps the asset stand out by linking biology to clinical readouts.
Regulatory planning
Chemomab Therapeutics Ltd. must keep IND, protocol, and later-stage filings tight because its orphan, immune-fibrotic programs face small trials and high FDA scrutiny; the U.S. IND clock is 30 days, so early agency feedback can cut delays and avoid costly protocol resets. That matters when each missed interaction can push a rare-disease program back by a full study cycle.
- IND review: 30 days
- Orphan trials need early alignment
- Fewer patients, higher risk
Business development and IP management
Chemomab Therapeutics Ltd. must keep building patent protection around its antibody and CCL24 know-how, because that is what defends the lead program and supports future deal talks. As a clinical-stage company in 2025, it also pursues partnering and non-dilutive funding to extend runway and widen commercialization paths without relying only on equity raises.
- File and defend core antibody patents
- Protect CCL24 know-how and data
- Seek partners for development and reach
- Pursue grants and non-dilutive cash
Chemomab Advances Nebokitug in Two Phase 2 Trials
Chemomab Therapeutics Ltd. focuses on advancing nebokitug through Phase 2 trials in primary sclerosing cholangitis and systemic sclerosis, while running translational and biomarker work to prove CCL24 blockade. It also keeps IND and later filings tight and protects its antibody and CCL24 know-how to support partnering and funding.
| Activity | Metric |
|---|---|
| Clinical trials | 2 lead Phase 2 programs |
| Regulatory | FDA IND review: 30 days |
| IP and partnering | Patents, data, non-dilutive cash |
Delivered as Displayed
Business Model Canvas
This Chemomab Therapeutics Ltd. Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. It shows a real section of the final file, so the layout, content, and formatting are the same as the completed deliverable. Once you buy, you’ll get instant access to this same ready-to-use document in its full version.
Resources
CM-101 lead asset
CM-101 is Chemomab Therapeutics Ltd.’s flagship clinical candidate and sole lead asset, a humanized monoclonal antibody that targets soluble CCL24. With 1 core program driving pipeline value, CM-101 anchors the company’s near-term scientific and commercial outlook.
CCL24 biology platform
Chemomab Therapeutics Ltd. centers its CCL24 biology platform on the role of CCL24 in inflammation and fibrosis, and uses it to screen assets and choose indications. It is the scientific base for CM-101, the company’s anti-CCL24 program, and supports its target and disease-selection strategy.
Patent and know-how portfolio
Patent and know-how are core assets for Chemomab Therapeutics Ltd: biotech IP can lock in exclusivity for up to 20 years from filing, and Chemomab’s antibody, method, and therapeutic-use claims help protect CM-101 and its follow-on programs. Strong protection also lifts partnering value, since licensors pay more for rights they can rely on.
Clinical data and trial infrastructure
PSC and SSc clinical datasets are Chemomab Therapeutics Ltd.'s core assets: they turn CM-101 into a measurable story through protocol design, endpoint data, and biomarker readouts that support each regulatory step. The same site network can be reused across studies, lowering startup friction and making trial execution a durable operating resource.
- PSC and SSc data build the evidence package.
- Endpoints and biomarkers prove signal.
- Site network can be reused.
Scientific team and Tel Aviv headquarters
Chemomab Therapeutics Ltd., founded in 2011 and based in Tel Aviv, Israel, depends on a lean scientific and management team to run drug development and corporate execution. In a single-asset biotech model, human capital is the key resource because it drives clinical progress, investor updates, and capital efficiency.
- Founded in 2011
- Headquartered in Tel Aviv
- Lean team supports one-asset focus
CM-101 and CCL24 Drive Chemomab’s Single-Asset Story
Chemomab Therapeutics Ltd.’s key resources are CM-101, its anti-CCL24 biology platform, and the IP and clinical data that protect and validate the program. Founded in 2011 and based in Tel Aviv, Israel, the company also relies on a lean team to run a single-asset model.
| Resource | Detail |
|---|---|
| Lead asset | CM-101 |
| Core platform | CCL24 biology |
| Company base | 2011, Tel Aviv |
Value Propositions
First-in-class anti-CCL24 approach
CM-101 is a first-in-class anti-CCL24 antibody that targets soluble CCL24, a differentiated inflammatory-fibrotic pathway. In 2 key indications, PSC and SSc, there is no standard treatment route for this mechanism, so Chemomab Therapeutics Ltd. can stand out with a novel clinical profile and a clearer commercial lane.
Potential disease-modifying therapy
Chemomab Therapeutics Ltd. positions nebokitug (CM-101) as a potential disease-modifying therapy, aiming to change the biology of fibrotic disease rather than only ease symptoms. That matters in high-unmet-need areas like primary sclerosing cholangitis, where no approved drug has yet shown clear disease reversal, and a durable effect could improve long-term outcomes.
Focus on high-unmet-need orphan diseases
Chemomab Therapeutics Ltd targets PSC, a rare disease affecting about 10-20 per million people, and systemic sclerosis, seen in roughly 50-300 per million, where treatment choices remain limited. Orphan status can speed development and support premium pricing; in the US, approved orphan drugs also get 7 years of exclusivity, which can draw specialist physicians.
Dual inflammation and fibrosis relevance
CCL24 sits at the intersection of inflammation and fibrosis, giving Chemomab Therapeutics Ltd a clear rationale in two hard-to-treat areas. With product CMC-501 in development for primary sclerosing cholangitis and systemic sclerosis, the same biology can support multiple indications and broaden the commercial case.
- CCL24 links inflammation and fibrosis
- One target, multiple disease uses
- PSC and systemic sclerosis are lead angles
Biomarker-driven development
Chemomab Therapeutics Ltd. uses translational biomarkers and mechanistic readouts to prove target engagement and track patient response, which makes its development path more measurable. For a partner or investor, stronger biomarker data lowers clinical risk and can support value creation in a market where biotech financing remains tight.
- Shows target engagement early
- Tracks patient response clearly
- Supports partner confidence
- Reduces trial risk and waste
Chemomab’s First-in-Class Fibrosis Play Targets Rare PSC and SSc Markets
Chemomab Therapeutics Ltd. offers nebokitug (CM-101), a first-in-class anti-CCL24 antibody aimed at PSC and systemic sclerosis, where treatment options are still limited. Its value is a disease-modifying angle on inflammation-fibrosis biology, with orphan-drug upside in rare markets and biomarker-based proof of target engagement.
| Metric | Data |
|---|---|
| PSC prevalence | 10-20 per million |
| SSc prevalence | 50-300 per million |
| US orphan exclusivity | 7 years |
Customer Relationships
KOL-led medical engagement
Chemomab keeps tight ties with hepatology and rheumatology KOLs because they shape trial endpoints, patient selection, and real-world adoption of CM-101 across fibrosis-driven diseases. These experts also help validate the disease rationale in PSC and systemic sclerosis, where unmet need remains high and 2 Phase 2 programs can hinge on credible clinical guidance.
Clinical trial participant support
Chemomab Therapeutics Ltd. builds trial relationships through clear patient communication, informed consent, safety checks, and retention support in PSC and SSc studies. With 2 lead clinical programs, keeping participants engaged through follow-up is essential for completing studies and generating reliable efficacy and safety data.
Regulator-facing scientific dialogue
Chemomab Therapeutics Ltd. keeps a regulator-facing scientific dialogue with health authorities to align on endpoints, trial design, and development plans. These evidence-based talks help define the path to later-stage studies and reduce the risk of costly protocol changes as the program advances.
Investor relations communication
Chemomab’s investor relations communication needs to keep shareholders and analysts updated on clinical data, trial milestones, and cash runway, because those signals shape access to new capital. In its latest public reporting, the company said it held cash and cash equivalents of $12.8 million at March 31, 2025, while continuing to advance its CXCL10 program.
- Shareholders watch data and milestones.
- Cash runway shapes financing risk.
- Clear updates support capital access.
Conference and publication outreach
Chemomab Therapeutics Ltd. uses conference and publication outreach to reach physicians and researchers with posters, talks, and papers, so the CM-101 program builds trust through education, not sales. This matters because CM-101 is still a specialist asset, and scientific visibility is a key signal of credibility.
- Poster and paper-led medical education
- Builds CM-101 scientific credibility
- Supports KOL and researcher engagement
CM-101’s Success Hinges on KOLs, Patients, and Regulators
Chemomab Therapeutics Ltd. builds customer ties around 3 groups: KOLs, trial patients, and regulators. The focus is on CM-101 in 2 Phase 2 programs, where expert input, patient retention, and endpoint alignment directly affect data quality and later adoption.
| Relationship | Latest data |
|---|---|
| Investor communication | $12.8 million cash and cash equivalents at March 31, 2025 |
Channels
Clinical trial sites
Clinical trial sites are Chemomab Therapeutics Ltd.'s main channel to patients for CM-101 today. These sites enroll participants, run study visits, and collect endpoint data, so site quality and recruitment speed drive trial execution and cash use.
Medical congresses
Medical congresses let Chemomab Therapeutics Ltd. present clinical and translational data to specialists in PSC, SSc, and fibrosis research, which helps build scientific awareness and credibility. This channel matters because PSC alone affects about 1 in 10,000 people and SSc about 50 to 300 per million, so reaching the right expert audience is key.
Peer-reviewed publications
Peer-reviewed publications validate Chemomab Therapeutics Ltd.'s mechanism and study results, and one strong paper can reach 3 key groups at once: clinicians, researchers, and potential partners. In rare-disease biotech, where patient pools are small and every data point matters, published evidence helps turn clinical findings into credibility, deal flow, and trial momentum.
Corporate website and press releases
Chemomab Therapeutics Ltd. uses its corporate website and press releases to publish pipeline updates, clinical data, and investor materials in one place. That keeps market messaging aligned and gives investors a single source for milestones on its lead asset, CM-101.
Press releases also help the Company time news around trial readouts and conference updates, so the market sees the same story at the same time.
- Centralizes pipeline and investor info
- Publishes trial and milestone news
- Supports consistent market messaging
Investor presentations and SEC filings
Chemomab Therapeutics Ltd. uses investor presentations and SEC filings as a direct capital-markets channel, telling investors about strategy, pipeline progress, cash runway, and trial results. These disclosures support fundraising and transparency; public companies file quarterly and annual reports, so the market can track updates fast.
- Shows strategy and clinical data
- Discloses cash runway
- Supports fundraising access
Chemomab’s Rare Disease Reach: Trials, Congresses, and Investor Visibility
Chemomab Therapeutics Ltd. mainly reaches patients through clinical trial sites, while congresses, publications, and its website/press releases carry CM-101 data to PSC and SSc specialists and investors. That mix matters in rare disease, where PSC affects about 1 in 10,000 people and SSc about 50 to 300 per million.
| Channel | Use | Key data |
|---|---|---|
| Trial sites | Enroll and follow patients | CM-101 studies |
| Congresses | Reach experts | PSC 1 in 10,000; SSc 50 to 300 per million |
Customer Segments
Primary sclerosing cholangitis patients
Primary sclerosing cholangitis patients are a core Chemomab Therapeutics Ltd. target group: PSC is a rare cholestatic liver disease, with prevalence estimates around 6–16 per 100,000 people and no approved drug that changes disease course. This makes the segment small but highly underserved, with urgent need for therapies that slow fibrosis and delay liver failure.
Systemic sclerosis patients
Systemic sclerosis is Chemomab Therapeutics Ltd.’s second main CM-101 target, and it is a rare but severe autoimmune fibrotic disease with high morbidity. The addressable group includes patients with skin and internal organ involvement; SSc prevalence is commonly cited at about 50,000-100,000 patients in the U.S., with diffuse disease carrying the highest risk.
Hepatologists and gastroenterologists
Hepatologists and gastroenterologists manage PSC diagnosis and treatment, and they are the core prescribers and trial investigators for CM-101. PSC is rare, with prevalence estimates of about 1 to 16 per 100,000 people in Western cohorts, so adoption will hinge on a small but influential specialist group at launch.
Rheumatologists and specialty centers
Rheumatologists and specialty centers are the key buyers and clinical gatekeepers in systemic sclerosis, a rare disease with estimated prevalence of 50 to 300 per million people. These centers handle the hardest cases and often run trials, so they shape referral, diagnosis, and uptake of Chemomab Therapeutics Ltd. treatments.
- Rare disease, high clinical influence
- Specialty centers run trials
- Drive adoption in complex cases
Pharma and biotech partners
Chemomab Therapeutics Ltd. can target larger pharma and biotech partners for development or commercialization deals, because buyers pay for differentiated assets in fibrosis and inflammation. Its lead-stage focus on CM-101/nebokitug makes strategic partnering a way to scale reach and funding beyond internal resources.
- Targets larger pharma and biotech buyers
- Focuses on fibrosis and inflammation assets
- Partners can extend reach and funding
Rare diseases, specialist buyers: Chemomab’s focused market opportunity
Chemomab Therapeutics Ltd. serves a narrow but high-need base: PSC and systemic sclerosis patients, both rare and specialist-led. PSC affects about 6–16 per 100,000 people, while systemic sclerosis is about 50–100 per 100,000; adoption runs through hepatologists, rheumatologists, and top referral centers, with pharma partners as the scale buyers.
| Segment | Key data |
|---|---|
| PSC | 6–16/100,000 |
| SSc | 50–100/100,000 |
| Buyers | Specialists, partners |
Cost Structure
Research and development spend
Chemomab Therapeutics Ltd. is a clinical-stage biotech, so research and development is the main cost driver; in 2024, R&D was $11.4 million, vs. $1.8 million in general and administrative costs. Most spend went to CM-101, including scientific staff, lab work, and translational studies, which is typical for a single-asset pipeline.
Clinical trial costs
Chemomab Therapeutics Ltd. clinical trial costs are heavy because multi-center PSC and SSc studies need patient recruitment, site payments, monitoring, and data management, while rare-disease enrollment stays slow and costly. In biotech, a mid-stage rare-disease trial can run into the tens of millions of dollars, so this line is usually a major cash burn driver.
Manufacturing and CMC costs
For Chemomab Therapeutics Ltd., manufacturing and CMC costs cover antibody process development, GMP runs, and release testing, and each clinical batch can run into the "hundreds of thousands" of dollars. These costs rise with every added patient and trial site, and CMC work stays critical long before any commercial launch.
General and administrative expenses
Chemomab Therapeutics Ltd.’s general and administrative expenses cover management, legal, finance, and compliance work, plus Nasdaq and SEC reporting. This is the public-company overhead that keeps corporate operations running, even when product spending shifts.
- Management and board support
- Legal, finance, and audit costs
- Nasdaq reporting and compliance
- Corporate operations backbone
Intellectual property and regulatory costs
Chemomab Therapeutics Ltd. spends steadily on patents, filings, and regulatory advice because exclusivity has to be defended while development packages are prepared. In biotech, U.S. patents can run 20 years from filing, so these costs stay routine for years, not months.
- Patent defense and filings are recurring
- Regulatory consulting supports submissions
- Exclusivity protection is a core spend
That makes intellectual property and regulatory costs a fixed part of Chemomab Therapeutics Ltd.'s development budget, alongside lab work and clinical operations.
Chemomab's Burn Is Still R&D-Driven
Chemomab Therapeutics Ltd. cost base is still dominated by R&D: 2024 R&D was $11.4 million, versus $1.8 million in G&A, reflecting CM-101 trial work, CMC, and rare-disease site costs. IP and regulatory spend also stays recurring, so cash burn remains tied to clinical progress.
| Cost item | 2024 |
|---|---|
| R&D | $11.4M |
| G&A | $1.8M |
Revenue Streams
No commercial product revenue yet
Chemomab Therapeutics Ltd. remains clinical-stage, so it had no approved therapy and no commercial product sales in FY2025. Product revenue was $0, and any cash inflows came from non-product sources such as financing or research-related collaboration income, not from marketed drugs.
Future CM-101 product sales
If CM-101 wins approval, Chemomab Therapeutics Ltd. could earn direct pharmaceutical sales, with primary launch markets in primary sclerosing cholangitis and systemic sclerosis. That is the company’s main long-term revenue pool, aimed at two rare diseases that together affect only a small patient base, with PSC prevalence estimated at 1-16 per 100,000 and SSc at 50-300 per million.
Licensing agreements
Chemomab Therapeutics Ltd. could license CM-101 or related IP to a larger partner, and an upfront fee would bring near-term cash while reducing its funding need for late-stage work. Licensing can also shift part of the development and commercialization risk, which matters for a company still advancing a Phase 2 asset.
Milestone and royalty income
Chemomab Therapeutics Ltd. can earn milestone payments from partnered programs when development or sales targets are hit, then add royalties once a drug is commercialized. In FY2025, the Company reported $0 revenue, so this line is still future upside, not a current cash engine.
- Development and sales milestones
- Royalties after launch
- FY2025 revenue: $0
Grants and non-dilutive funding
Grants and public support can fund Chemomab Therapeutics Ltd.'s rare-disease and translational work, especially early studies that are hard to finance with sales alone. Non-dilutive money helps cover R&D without issuing new shares, so it limits equity dilution.
- Best fit: rare-disease programs
- Uses: early development costs
- Benefit: no new-share dilution
Chemomab Remains Pre-Commercial With No FY2025 Product Sales
Chemomab Therapeutics Ltd. had no product sales in FY2025, so Revenue Streams were still pre-commercial. Cash inflows were limited to non-product sources such as collaboration income, grants, and financing, while CM-101 remains the main future sales driver.
| Revenue stream | FY2025 |
|---|---|
| Product sales | $0 |
| Collaboration/grants | Non-product |
| Future CM-101 sales | Post-approval |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.